Autogenic Inhibition Versus Reciprocal Inhibition Muscle Energy Techniques Effect on Swimming Performance on Swimmers With Scapular Dyskinesis

January 1, 2024 updated by: Foundation University Islamabad
Swimming can cause shoulder pain due to scapular dyskinesis. Proper scapula movement is necessary for efficient swimming strokes and to avoid injury. Studying the effects of autogenic and reciprocal inhibition muscle energy techniques on swimmers with scapular dyskinesis can lead to effective interventions and reduce shoulder injuries

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Efficient swimming strokes require proper positioning of the scapula. Scapular dyskinesis (SD) is a condition where normal scapular kinematics are altered due to injury or changes in muscle activation. Swimmers, who are considered overhead athletes, have risk of developing SD. Even individuals who do not experience symptoms can have SD, and it may lead to future shoulder injuries. Early diagnosis and treatment of this condition can prevent it from progressing and minimize the risk of injury. Additionally, using autogenic and reciprocal inhibition muscle energy techniques can enhance the activation of the appropriate muscles responsible for scapular movement, which can lead to more effective interventions, improved swimming performance, and reduced injury risk. he intervention protocol (Muscle energy techniques to the upper fibers of the Trapezius, Levator Scapulae, Pectoralis Major, Latissimus Dorsi) will be conducted for 8-14 minutes over 3 weeks with 12 sessions/4 times a week. Outcomes measure will be assessed after the intervention period and data will be analyzed.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
34

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab
      • Rawalpindi, Punjab, Pakistan, 46000
        • Recruiting
        • Foundation University College of Physical Therapy
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Swimmers with at least four times training per week
  • Does not have any shoulder pain or injury or operation to the shoulders
  • Positive Scapular Dyskinesis diagnosis test
  • Freestyle (also known as a front crawl) swimming stroke

Exclusion criteria:

  • Shoulder pain in the last six months
  • History of shoulder surgery or fracture within the last six months
  • Frequent practice of physical activity in any other sport
  • Negative result of the Scapular Dyskinesis test
  • Other swimming strokes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group A (Autogenic inhibition muscle energy technique)
12 sessions will be conducted over a period of 4 weeks with 3 days per week Frequency: 12 sessions, four times a week for 3 consecutive weeks Time duration: apporx. 8 to 10 minutes
Procedure: Autogenic Inhibition-MET
Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
Experimental: Group B (Reciprocal inhibition muscle energy technique)

12 sessions will be conducted over a period of 3 weeks with 4 days per week

Frequency: 12 sessions, four times a week for 3 consecutive weeks Time duration: apporx. 8 to 10 minutes
Procedure: Reciprocal Inhibition-MET protocol
Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Stroke velocity
Time Frame: 3 weeks
Stroke velocity will be assessed using KINOVEA
3 weeks
Stroke rate
Time Frame: 3 weeks
Stroke rate will be assessed using KINOVEA
3 weeks
stroke length
Time Frame: 3 weeks
Stroke length will be assessed using KINOVEA
3 weeks
Total strokes
Time Frame: 03 Week
Total strokes will be assessed using KINOVEA
03 Week
Stroke time
Time Frame: 03 Week
Stroke time will be assessed using KINOVEA
03 Week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Foundation University Islamabad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 30, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 15, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 1, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 1, 2024

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 11, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 11, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 1, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FUI/CTR/2023/27

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings